Pfizer (PFE) Cash from Discontinued Operations (2010 - 2022)

Pfizer has disclosed Cash from Discontinued Operations across 9 years of filings, most recently posting 5000000.0 for Q3 2022.

• In Q3 2022, Cash from Discontinued Operations fell 129.41% year-over-year to 5000000.0; the TTM figure through Oct 2022 stood at 332000000.0 (down 115.84% YoY), while the FY2021 annual figure was 343000000.0, down 108.88% from the prior year.
• Cash from Discontinued Operations climbed to 5000000.0 in Q3 2022, from 327000000.0 in the prior quarter.
• Over the last five years, Cash from Discontinued Operations for PFE reached as high as 2414000000.0 in Q3 2020 and fell as low as 327000000.0 in Q4 2021.
• The 3-year median for Cash from Discontinued Operations is 17000000.0 (2021), against an average of 564428571.43.
• Annual changes were most pronounced in 2021 — Cash from Discontinued Operations sank 98.07% — and 2022, when it plunged 129.41%.
• A 3-year view of Cash from Discontinued Operations shows it stood at 2414000000.0 in 2020, then plunged by 113.55% to 327000000.0 in 2021, then jumped by 98.47% to 5000000.0 in 2022.
• According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 5000000.0, 327000000.0, and 17000000.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.